Thank you for being one of our most loyal readers. Please consider supporting community journalism by subscribing.
CLAYTON — Researchers at Grifols hope they can use plasma from recovered COVID-19 patients to develop a targeted treatment for the coronavirus, the company announced Wednesday.
Grifols is working with the U.S. Biomedical Advanced Research Development Authority, the Food and Drug Administration and federal health agencies to collect plasma from recovering COVID-19 patients, a company news release said.
Grifols plans to use its Clayton plant to turn the plasma into a hyperimmune globulin and then support clinical studies to determine if hyperimmune globulin therapy can successfully treat COVID-19.
Dr. Stephen Hahn, commissioner of the FDA, applauded the collaborative effort to find a treatment for a disease that has killed thousands worldwide.
“There is a cross-agency effort about … convalescent plasma,” Hahn said. “This is an exciting area. The immune response could provide a benefit to patients.”